IDH mutation – Medxy AI

Adjuvant Temozolomide for IDH-Mutated Anaplastic Astrocytoma: Final CATNON Results Confirm a Decade of Survival Benefit

By MedXY 01/05/2026

The final analysis of the EORTC CATNON trial reveals that 12 cycles of adjuvant temozolomide significantly extend overall survival to 12.5 years in IDH-mutated anaplastic astrocytoma, whereas concurrent temozolomide provides no added clinical benefit.

Clinical Updates Hematology-Oncology news Specialties

Promising Frontline Triplet Therapies for IDH-Mutated AML Patients Ineligible for Intensive Chemotherapy

By MedXY 09/09/2025

Triplet regimens combining hypomethylating agents, venetoclax, and IDH inhibitors demonstrate high remission rates and survival in intensive chemotherapy-ineligible IDH-mutant AML patients, warranting further comparative studies against approved doublet therapies.

Clinical Updates news Oncology Specialties

EMA Recommends Voranigo for IDH-Mutant Grade 2 Glioma: A New Era in Targeted Brain Tumor Therapy

By MedXY 07/30/2025

The EMA’s CHMP recommends Voranigo, a dual IDH1/2 inhibitor, for grade 2 IDH-mutant gliomas, based on phase 3 INDIGO trial results demonstrating significant improvement in progression-free survival and delayed need for further therapy.